# Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder

> **NCT00877487** · PHASE4 · COMPLETED · sponsor: **Shire** · enrollment: 123 (actual)

## Conditions studied

- Attention-Deficit/Hyperactivity Disorder

## Interventions

- **DRUG:** SPD489 (Lisdexamfetamine dimesylate)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00877487
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04-30
- **Primary completion:** 2010-07-08
- **Final completion:** 2010-07-08
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2021-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00877487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00877487, "Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00877487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*